 |
|
A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea
Jaemin Shim, Young Keun On, Sun U. Kwon, Gi-Byoung Nam, Moon-Hyoung Lee, Hyung-Wook Park, Keun-Sik Hong, Nam-Ho Kim, Pierre Amarenco, Seung-Woon Rha, Dong-Gu Shin, Joung-Ho Rha, Young-Hoon Kim
Korean J Intern Med. 2021;36(4):906-913. Published online 2021 Jun 11 DOI: https://doi.org/10.3904/kjim.2020.217
|
|
Citations to this article as recorded by
 A Real-World, Prospective, Observational Study of Rivaroxaban on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-Valvular Atrial Fibrillation: XARENAL
Il-Young Oh, Chang Hoon Lee, Eue-Keun Choi, Hong Euy Lim, Yong-Seog Oh, Jong-Il Choi, Min-Soo Ahn, Ju Youn Kim, Nam-Ho Kim, Namsik Yoon, Martin Sandmann, Kee-Joon Choi
Korean Circulation Journal.2025; 55(2): 121. CrossRef Efficacy and Safety of Rivaroxaban in Prevention and Therapy of Thromboembolic Events in Patients with Nonvalvular Atrial Fibrillation
Tamara Kovačević Preradović, Siniša Miljković, Ljiljana Kos, Aziz Šukalo, Una Glamočlija, Amna Tanović Avdić, Meliha Mehić
Journal of the Practice of Cardiovascular Sciences.2023; 9(2): 110. CrossRef Rivaroxaban: striking two birds with one stone
Yae Min Park
The Korean Journal of Internal Medicine.2021; 36(4): 842. CrossRef
|